# 此超級綜合評分是基於以下評分的加權平均結果。

*biotech · news · 2026-05-28 · MarketScreener*

## Key points

- Trader 超級評分使用四個月的每股盈餘修正期作為關鍵因素。
- Investor 超級評分獨特地整合了一年期的每股盈餘修正指標，與 Trader 的方法不同。
- Global 評分要求至少有五個不同綜合子評分中的四個涵蓋，才能進行計算。
- Quality 綜合評分計算僅在公司被至少兩個子評分涵蓋時進行。

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/renovorx-gets-fda-orphan-drug-designation-for-oxaliplatin-to-treat-pancreatic-cancer-ce7f5ddada8cf624)

---

Canonical: https://newsio.io/zh-TW/n/74f51284-c7c7-4608-973a-40c7e9e7ce11/
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works